A case for reprising and redefining melancholia

Canadian Journal of Psychiatry

Volumn 58, Issue 4, 2013, Pages 183-189

  Parker, Gordon ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Classification; Depression; Melancholia; Nonmelancholic disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUSTMENT DISORDER; CIRCADIAN RHYTHM; CLINICAL FEATURE; DEPRESSIVE PSYCHOSIS; DEXAMETHASONE SUPPRESSION TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; ENDOGENOUS DEPRESSION; FATIGUE; HISTORY OF MEDICINE; HUMAN; MAJOR DEPRESSION; MELANCHOLIA; META ANALYSIS (TOPIC); MONOAMINERGIC SYSTEM; MOOD; PARKINSON DISEASE; PERSONALITY DISORDER; PSYCHOTHERAPY; REMISSION; REVIEW; SLEEP DISORDER; TREATMENT RESPONSE;

EID: 84878283358     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800402     Document Type: Review

References (28)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 3rd ed. Washington (DC): APA; 1980.
2. World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders - clinical descriptions and diagnostic guidelines. Geneva (CH): WHO; 1992.
3. Parker G, Manicavasagar V. Modelling and managing the depressive disorders. Cambridge (GB): Cambridge University Press; 2005.
4. Horwitz AV, Wakefield JC. The loss of sadness. New York (NY): Oxford University Press; 2007.
5. Parker G. Diagnosis of depressive disorders. In: Herman H, Maj M, Sartorius N, editors. Depressive disorders. 3rd ed. West Sussex (GB); Wiley-Blackwell; 2009. p 1-26.
6. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol. 2002;5: 193-197.
7. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
8. Parker G, Fletcher K. Treating depression with the evidence-based psychotherapies: a critique of the evidence. Acta Psychiatr Scand. 2007;115: 352-359.
9. Wiliams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132(9): 743-756.
10. Parker G, Fink M, Shorter E, et al. Issues of DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry. 2010;167(7): 745-747. Editorial.
11. Jackson S W. Melancholia and depression: from hippocratic times to modern times. New Haven (CT): Yale University Press; 1986.
12. Parker G, Hadzi-Pavlovic D. Melancholia: a disorder of movement and mood. A phenomenological and neurobiological review. New York (NY): Cambridge University Press; 1996.
13. Taylor MA, Fink M. Melancholia. The diagnosis, pathophysiology, and treatment of depressive illness. Cambridge (GB): Cambridge University Press; 2006.
14. Berrios GE. Melancholia and depression during the 19th century. Br J Psychiatry. 1988;153: 298-304.
15. Kendell RE. Clinical validity. In: Robins LN, Barrett JE, editors. The validity of psychiatric diagnosis. New York (NY): Raven Press; 1989. p 305-323.
16. Lewis AJ. 1931. A clinical and historical survey of depressive states based on the study of 61 cases [doctoral thesis]. [Adelaide (AU)]: University of Adelaide.
17. Kiloh LG, Garside RF. Depression: a multivariate study of Sir Aubrey Lewis's data on melancholia. Aust N Z J Psychiatry. 1977;11: 149-156.
18. Parker G, Hadzi-Pavlovic D. Old data, new interpretation: a re-analysis of Sir Aubrey Lewis' MD thesis. Psychol Med. 1993;23: 859-870.
19. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): APA; 1994.
20. Parker G, Fletcher K, Barrett M, et al. Inching towards Bethlehem: mapping melancholia. J Affect Disord. 2010;123: 291-298.
21. Parker G, McCraw S, Blanch B, et al. Discriminating melancholic and non-melancholic depression by prototypic clinical features. J Affect Disord. 2102;144: 199-207.
22. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry. 1965;111: 659-674.
23. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington (DC): APA; 1987.
24. Fairchild CJ, Rush AJ, Vasavad N, et al. Which depressions respond to placebo? Psychiatr Res. 1986;18: 217-226.
25. McGrath PJ, Khan Ahsan Y, Trivedi MH, et al. Response to the selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry. 2008;69:12.
26. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord. 1996;39: 1-6.
27. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand. 2002;106: 168-170.
28. Parker G, Roy K, Wilhelm K, et al. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry. 2001;62: 117-125.